S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
15 A.I. Trading Opportunities a Day (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Wall Street Veteran: "A New Wave of Crashes Will Rock US Stocks" (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
15 A.I. Trading Opportunities a Day (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Wall Street Veteran: "A New Wave of Crashes Will Rock US Stocks" (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
15 A.I. Trading Opportunities a Day (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Wall Street Veteran: "A New Wave of Crashes Will Rock US Stocks" (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
15 A.I. Trading Opportunities a Day (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Wall Street Veteran: "A New Wave of Crashes Will Rock US Stocks" (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
NASDAQ:FOLD

Amicus Therapeutics (FOLD) Stock Forecast, Price & News

$11.11
-0.03 (-0.27%)
(As of 05/26/2023 08:47 PM ET)
Compare
Today's Range
$10.99
$11.24
50-Day Range
$10.72
$12.19
52-Week Range
$7.34
$13.84
Volume
1.37 million shs
Average Volume
2.39 million shs
Market Capitalization
$3.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.20

Amicus Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
36.8% Upside
$15.20 Price Target
Short Interest
Bearish
7.53% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.28
Upright™ Environmental Score
News Sentiment
0.17mentions of Amicus Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$664,876 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.48) to $0.13 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

642nd out of 1,010 stocks

Pharmaceutical Preparations Industry

322nd out of 494 stocks


FOLD stock logo

About Amicus Therapeutics (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.

Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Stock News Headlines

FOLD Amicus Therapeutics, Inc.
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
Free A.I. Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Berenberg Bank Keeps Their Hold Rating on Amicus (FOLD)
SVB Securities Keeps Their Buy Rating on Amicus (FOLD)
8-K: AMICUS THERAPEUTICS, INC.
See More Headlines
Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Company Calendar

Last Earnings
3/01/2023
Today
5/29/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FOLD
CUSIP
03152W10
Employees
496
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$15.20
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+36.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-236,570,000.00
Pretax Margin
-63.47%

Debt

Sales & Book Value

Annual Sales
$329.23 million
Book Value
$0.36 per share

Miscellaneous

Free Float
276,778,000
Market Cap
$3.14 billion
Optionable
Optionable
Beta
0.81

Social Links


Key Executives

  • Bradley Lewis CampbellBradley Lewis Campbell
    President, Chief Executive Officer & Director
  • Pat O’Sullivan
    Chief Technical Operations Officer
  • Daphne E. Quimi
    Chief Financial Officer
  • Jill Weimer
    Chief Science Officer
  • Mitchell Goldman
    Chief Medical Officer













FOLD Stock - Frequently Asked Questions

Should I buy or sell Amicus Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FOLD shares.
View FOLD analyst ratings
or view top-rated stocks.

What is Amicus Therapeutics' stock price forecast for 2023?

5 Wall Street analysts have issued 1-year price targets for Amicus Therapeutics' stock. Their FOLD share price forecasts range from $11.00 to $17.00. On average, they anticipate the company's stock price to reach $15.20 in the next twelve months. This suggests a possible upside of 36.8% from the stock's current price.
View analysts price targets for FOLD
or view top-rated stocks among Wall Street analysts.

How have FOLD shares performed in 2023?

Amicus Therapeutics' stock was trading at $12.21 at the start of the year. Since then, FOLD shares have decreased by 9.0% and is now trading at $11.11.
View the best growth stocks for 2023 here
.

When is Amicus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our FOLD earnings forecast
.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings results on Wednesday, March, 1st. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.06. The biopharmaceutical company earned $88.20 million during the quarter, compared to the consensus estimate of $86.95 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 153.68% and a negative net margin of 60.63%.

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (9.78%), Avoro Capital Advisors LLC (9.66%), BlackRock Inc. (6.98%), JPMorgan Chase & Co. (4.86%), State Street Corp (3.94%) and Palo Alto Investors LP (3.72%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends
.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $11.11.

How much money does Amicus Therapeutics make?

Amicus Therapeutics (NASDAQ:FOLD) has a market capitalization of $3.14 billion and generates $329.23 million in revenue each year. The biopharmaceutical company earns $-236,570,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

How many employees does Amicus Therapeutics have?

The company employs 496 workers across the globe.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The official website for the company is www.amicusrx.com. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at afaughnan@amicusrx.com, or via fax at 609-662-2001.

This page (NASDAQ:FOLD) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -